Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TAK-919

            Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-919

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2021

            Details:

            This interim analysis showed that binding antibody and neutralizing antibody titers were elevated at 28 days after the second dose in 100% of people vaccinated with two 0.5ml doses of TAK-919 given 28 days apart.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bordetella pertussis protective antigen,Diphtheria toxoid,Tetanus toxoid

            Therapeutic Area: Infections and Infectious Diseases Product Name: Squarekids

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination March 31, 2021

            Details:

            Daiichi Sankyo will terminate its marketing alliance agreement for the Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine and its joint development agreement on pentavalent combination vaccine with Sanofi K.K.